Cargando…
Neuroprotective Effects of Sodium Butyrate and Monomethyl Fumarate Treatment through GPR109A Modulation and Intestinal Barrier Restoration on PD Mice
Research has connected Parkinson’s disease (PD) with impaired intestinal barrier. The activation of G-protein-coupled receptor 109A (GPR109A) protects the intestinal barrier by inhibiting the NF-κB signaling pathway. Sodium butyrate (NaB), which is a GPR109A ligand, may have anti-PD effects. The cur...
Autores principales: | Xu, Rui-Chen, Miao, Wen-Teng, Xu, Jing-Yi, Xu, Wen-Xin, Liu, Ming-Ran, Ding, Song-Tao, Jian, Yu-Xin, Lei, Yi-Han, Yan, Ning, Liu, Han-Deng |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9571500/ https://www.ncbi.nlm.nih.gov/pubmed/36235813 http://dx.doi.org/10.3390/nu14194163 |
Ejemplares similares
-
Monomethyl fumarate promotes Nrf2-dependent neuroprotection in retinal ischemia-reperfusion
por: Cho, Hongkwan, et al.
Publicado: (2015) -
Dimethyl Fumarate and Monomethyl Fumarate Promote Post-Ischemic Recovery in Mice
por: Yao, Yang, et al.
Publicado: (2016) -
Pharmacokinetics and Bioavailability of Monomethyl Fumarate Following a Single Oral Dose of Bafiertam™ (Monomethyl Fumarate) or Tecfidera(®) (Dimethyl Fumarate)
por: Lategan, Thomas W., et al.
Publicado: (2021) -
Monomethyl fumarate prevents alloimmune rejection in mouse heart transplantation by inducing tolerogenic dendritic cells: Monomethyl fumarate prevents alloimmune rejection
por: Chen, Juntao, et al.
Publicado: (2023) -
Butyrate Suppresses Glucose Metabolism of Colorectal Cancer Cells via GPR109a-AKT Signaling Pathway and Enhances Chemotherapy
por: Geng, Hong-Wei, et al.
Publicado: (2021)